Precision Bio director’s 21,000 RSUs vest

Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.

PRECISION BIOSCIENCES INC director Germano Geno J reported a routine equity compensation event. On May 20, 2026, 21,000 Restricted Stock Units vested and were settled into 21,000 shares of Common Stock at a price of $0.00 per share. Following this vesting, he directly holds 44,883 shares of Common Stock. The RSUs were originally granted on June 3, 2025 and were scheduled to vest on the earlier of June 3, 2026 or the day immediately before the company’s next annual stockholders’ meeting, subject to continued service.

Insider Trade Summary

21,000 shares exercised/converted

Exercise 2 txns

Insider Germano Geno J

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	21,000	$0.00	$0.00
Exercise	Common Stock	21,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 44,883 shares (Direct)

Footnotes (3)

1. F1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

RSUs vested: 21,000 units Shares issued from RSUs: 21,000 shares Post-transaction holdings: 44,883 shares +3 more

6 metrics

RSUs vested 21,000 units Restricted Stock Units vested on May 20, 2026

Shares issued from RSUs 21,000 shares Common Stock received upon RSU vesting

Post-transaction holdings 44,883 shares Common Stock held directly after transaction

RSU grant date June 3, 2025 Original grant of RSUs to director

Vesting trigger Earlier of June 3, 2026 or pre-annual meeting RSU vesting condition tied to time and service

Exercise price $0.00 per share Conversion of RSUs into Common Stock

Key Terms

Restricted Stock Units, vesting, contingent right, Common Stock, +1 more

5 terms

Restricted Stock Units financial

"Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Common Stock financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"…the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date…"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Precision Biosciences (DTIL) disclose for Germano Geno J?

Precision Biosciences disclosed that director Germano Geno J had 21,000 Restricted Stock Units vest into 21,000 shares of Common Stock on May 20, 2026. This was a compensation-related equity vesting, not an open-market stock purchase or sale.

How many Precision Biosciences (DTIL) shares does Germano Geno J hold after this Form 4?

After the RSU vesting, Germano Geno J directly holds 44,883 shares of Precision Biosciences Common Stock. This total reflects the addition of 21,000 newly issued shares from vested RSUs and indicates his post-transaction equity position reported in the filing.

Was the Precision Biosciences (DTIL) Form 4 an open-market trade or an RSU vesting?

The Form 4 reflects an RSU vesting, not an open-market trade. 21,000 Restricted Stock Units converted into 21,000 shares of Common Stock at $0.00 per share, consistent with equity compensation rather than a discretionary market purchase or sale.

What were the vesting terms for Germano Geno J’s RSUs at Precision Biosciences (DTIL)?

The RSUs were granted on June 3, 2025 and vested on the earlier of June 3, 2026 or the day immediately prior to the company’s next annual stockholders’ meeting. Vesting was conditioned on Germano Geno J’s continued service through the applicable vesting date.

How many Restricted Stock Units vested for Germano Geno J at Precision Biosciences (DTIL)?

A total of 21,000 Restricted Stock Units vested for Germano Geno J. Each RSU represented a contingent right to receive one share of Precision Biosciences Common Stock, resulting in 21,000 new shares issued to him upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 07:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Germano Geno J

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW ST., SUITE A-100

(Street)

DURHAM NORTH CAROLINA 27701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		M		21,000(1)	A	(2)	44,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	05/20/2026		M			21,000	(3)	(3)	Common Stock	21,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Dario Scimeca Attorney-in-Fact for Geno J. Germano	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)